Empirical risk scores for stroke and bleeding risk in AF
Stroke risk scores . | Bleeding risk scores . |
---|---|
CHADS212 | ATRIA15 |
Congestive heart failure (1 point) | Anemia (3 points) |
Hypertension (1 point) | Severe renal disease (3 points) |
Age ≥75 (1 point) | Age ≥75 (2 points) |
Diabetes (1 point) | Prior bleeding (1 point) |
Stroke or TIA (2 points) | Hypertension (1 point) |
CHA2DS2-VASc13 | HAS-BLED16 |
Congestive heart failure (1 point) | Hypertension (1 point) |
Hypertension (1 point) | Abnormal liver or renal function (1 point each) |
Age ≥75 (2 points) | Stroke (1 point) |
Diabetes (1 point) | Bleeding (1 point) |
Stroke or TIA (2 points) | Labile international normalized ratio (1 point) |
Vascular disease (1 point) | Elderly: age >65 (1 point) |
Age 65-74 (1 point) | Drugs or alcohol (1 point each) |
Sex category (1 point for female, 0 for male) | |
ORBIT17 | |
Older age (1 point) | |
Reduced hemoglobin/anemia (2 points) | |
Bleeding history (2 points) | |
Insufficient kidney function (1 point) | |
Treatment with antiplatelet |
Stroke risk scores . | Bleeding risk scores . |
---|---|
CHADS212 | ATRIA15 |
Congestive heart failure (1 point) | Anemia (3 points) |
Hypertension (1 point) | Severe renal disease (3 points) |
Age ≥75 (1 point) | Age ≥75 (2 points) |
Diabetes (1 point) | Prior bleeding (1 point) |
Stroke or TIA (2 points) | Hypertension (1 point) |
CHA2DS2-VASc13 | HAS-BLED16 |
Congestive heart failure (1 point) | Hypertension (1 point) |
Hypertension (1 point) | Abnormal liver or renal function (1 point each) |
Age ≥75 (2 points) | Stroke (1 point) |
Diabetes (1 point) | Bleeding (1 point) |
Stroke or TIA (2 points) | Labile international normalized ratio (1 point) |
Vascular disease (1 point) | Elderly: age >65 (1 point) |
Age 65-74 (1 point) | Drugs or alcohol (1 point each) |
Sex category (1 point for female, 0 for male) | |
ORBIT17 | |
Older age (1 point) | |
Reduced hemoglobin/anemia (2 points) | |
Bleeding history (2 points) | |
Insufficient kidney function (1 point) | |
Treatment with antiplatelet |
Modified from Steinberg et al.67